Cerus (CERS) Scheduled to Post Quarterly Earnings on Wednesday

Cerus (NASDAQ:CERS) is set to post its quarterly earnings results after the market closes on Wednesday, October 30th. Analysts expect Cerus to post earnings of ($0.03) per share for the quarter. Investors interested in registering for the company’s conference call can do so using this link.

Cerus (NASDAQ:CERS) last released its earnings results on Thursday, August 1st. The biotechnology company reported ($0.03) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.04) by $0.01. Cerus had a negative return on equity of 44.27% and a negative net margin of 14.15%. The business had revenue of $45.08 million for the quarter, compared to the consensus estimate of $42.50 million. During the same quarter in the previous year, the business earned ($0.07) earnings per share. On average, analysts expect Cerus to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Cerus Stock Performance

Shares of NASDAQ CERS opened at $1.63 on Wednesday. The stock has a market capitalization of $301.37 million, a PE ratio of -9.59 and a beta of 1.18. Cerus has a 52 week low of $1.23 and a 52 week high of $2.59. The stock has a 50 day moving average price of $1.96 and a 200 day moving average price of $1.92. The company has a debt-to-equity ratio of 1.29, a quick ratio of 1.83 and a current ratio of 2.51.

Insider Buying and Selling at Cerus

In related news, CFO Kevin Dennis Green sold 28,385 shares of the business’s stock in a transaction that occurred on Tuesday, September 3rd. The stock was sold at an average price of $2.18, for a total value of $61,879.30. Following the completion of the sale, the chief financial officer now directly owns 590,365 shares in the company, valued at approximately $1,286,995.70. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. In other Cerus news, insider Richard J. Benjamin sold 21,605 shares of the company’s stock in a transaction on Friday, August 2nd. The stock was sold at an average price of $2.50, for a total transaction of $54,012.50. Following the completion of the sale, the insider now directly owns 438,007 shares in the company, valued at $1,095,017.50. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Kevin Dennis Green sold 28,385 shares of the firm’s stock in a transaction on Tuesday, September 3rd. The shares were sold at an average price of $2.18, for a total value of $61,879.30. Following the completion of the sale, the chief financial officer now directly owns 590,365 shares in the company, valued at approximately $1,286,995.70. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders own 3.40% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, Stifel Nicolaus lowered their price objective on shares of Cerus from $6.00 to $3.00 and set a “buy” rating on the stock in a research note on Thursday, October 17th. Two investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat, Cerus has an average rating of “Moderate Buy” and an average price target of $3.63.

Cerus Company Profile

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.